MHMary Ann Hardwicke

Mary Ann Hardwicke

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mary Ann Hardwicke has a total of 12 co-authors. Here are the top co-authors by number of shared publications:

  • Catherine A. Oleykowski

    Oncology Biology, 2Medicinal Chemistry, 3Enzymology and Mechanistic Pharmacology, GlaxoSmithKline, Collegeville, Pennsylvania

    1 shared publication
  • Dashyant Dhanak

    Oncology Biology, 2Medicinal Chemistry, 3Enzymology and Mechanistic Pharmacology, GlaxoSmithKline, Collegeville, Pennsylvania

    1 shared publication
  • David Sutton

    Oncology Biology, 2Medicinal Chemistry, 3Enzymology and Mechanistic Pharmacology, GlaxoSmithKline, Collegeville, Pennsylvania

    1 shared publication
  • Denis Patrick

    Oncology Biology, 2Medicinal Chemistry, 3Enzymology and Mechanistic Pharmacology, GlaxoSmithKline, Collegeville, Pennsylvania

    1 shared publication
  • Jamin Wang

    Oncology Biology, 2Medicinal Chemistry, 3Enzymology and Mechanistic Pharmacology, GlaxoSmithKline, Collegeville, Pennsylvania

    1 shared publication
  • Jerry L. Adams

    Oncology Biology, 2Medicinal Chemistry, 3Enzymology and Mechanistic Pharmacology, GlaxoSmithKline, Collegeville, Pennsylvania

    1 shared publication

Latest Publications

  • GSK1070916, a potent Aurora B/C kinase inhibitor with broad antitumor activity in tissue culture cells and human tumor xenograft models

    by Mary Ann Hardwicke, Catherine A. Oleykowski, Ramona Plant, Jamin Wang, Qiaoyin Liao, Katherine Moss, Ken Newlander, Jerry L. Adams, Dashyant Dhanak, Jingsong Yang, et al.

    The protein kinases, Aurora A, B, and C have critical roles in the regulation of mitosis and are frequently overexpressed or amplified in human tumors. GSK1070916, is a novel ATP competitive inhibitor that is highly potent and selective for Aurora B/C kinases. Human tumor cells treated with GSK1070916 show dose-dependent inhibition of phosphorylation on serine 10 of Histone H3, a substrate specific for Aurora B kinase. Moreover, GSK1070916 inhibits the proliferation of tumor cells with EC50 values of <10 nmol/L in over 100 cell lines spanning a broad range of tumor types. Although GSK1070916 has potent activity against proliferating cells, a dramatic shift in potency is observed in primary, nondividing, normal human vein endothelial cells, consistent with the proposed mechanism. We further determined that treated cells do not arrest in mitosis but instead fail to divide and become polyploid, ultimately leading to apoptosis. GSK1070916 shows dose-dependent inhibition of phosphorylation of an Aurora B–specific substrate in mice and consistent with its broad cellular activity, has antitumor effects in 10 human tumor xenograft models including breast, colon, lung, and two leukemia models. These results show that GSK1070916 is a potent Aurora B/C kinase inhibitor that has the potential for antitumor activity in a wide range of human cancers. [Mol Cancer Ther 2009;8(7):1808–17]